ML364

Research use only, not for human use.

A potent, selective, reversible deubiquitinase USP2 inhibitor with IC50 of 1.1 uM in biochemical assay.

A potent, selective, reversible deubiquitinase USP2 inhibitor with IC50 of 1.1 uM in biochemical assay; also inhibits USP8 (IC50=0.95 uM), shows no against caspase 6/7, MMP1, MMP9 and USP15 and a panel of 102 kinase; increases cellular cyclin D1 degradation and causes cell cycle arrest and shows antiproliferative in cancer cell lines; also decreases homologous recombination-mediated DNA repair.

ML364 (5-20 μM; 24-48 hours) inhibits LnCAP and MCF7 cells viability in a dose-dependent manner.?ML364 (10 μM; 2-24 hours) reduces cyclin D1 protein levels in a time-, dose-, and proteasome-dependent manner in HCT116 cells and Mino cells. Cell Viability Assay Cell Line:LnCAP, MCF7 cells Concentration:5, 10, 15, 20 μM Incubation Time:24, 48 hours Result:LnCAP and MCF7 cells showed a decrease in cell viability in a dose-dependent manner.Western Blot AnalysisCell Line:HCT116, Mino cells Concentration:2, 4, 8, 16, 24 hours Incubation Time:10 μM Result:Reduced cyclin D1 protein levels in a time-, dose-, and proteasome-dependent manner in HCT116 cells and Mino cells.

——

ML 364 | ML-364

Proteasome/Ubiquitin

DUB

USP2

Cancer

——

1991986-30-1

517.5432296

C24H18F3N3O3S2

>98% (HPLC)

DMSO: ≥ 33 mg/mL

O=C(NC1=NC(C2=CC=CC=C2)=CS1)C3=CC=C(C(F)(F)F)C=C3NS(=O)(C4=CC=C(C)C=C4)=O

Benzamide, 2-[[(4-methylphenyl)sulfonyl]amino]-N-(4-phenyl-2-thiazolyl)-4-(trifluoromethyl)-

(-20℃)

With Ice Pack

≥ 2 years